" class="no-js "lang="en-US"> Matt McKnight - Medtech Alert
Friday, August 29, 2025
Matt McKnight

Matt McKnight

About Matt McKnight

Matthew McKnight is Chief Commercial Officer of Ginkgo Bioworks. Matt is a Board Advisor at Decision Resources Group, a Board Member of SmithRx, and he spent seven years as an investor at IndUS Growth Partners. Prior to Ginkgo, Matt worked supporting business development at Palantir Technologies. Early in his career, Matt served as an officer in the United States Marine Corps. Matt completed a degree in History at Dartmouth College and is a graduate of the joint degree program at the Harvard Business School and the Harvard Kennedy School of Government, where he was a Zuckerman Fellow.

Related Story

Ginkgo Bioworks and the Rwanda Development Board Announce Plans to Develop and Implement New Biosecurity Capabilities in Rwanda

August 12 2022

Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, and the Rwanda Development […]

Concentric by Ginkgo Crosses 10 Million Samples Tested and Expands Testing and Sequencing Capabilities to Detect Monkeypox and Other Pathogens, as Part of Scaling Its Global Biosecurity Infrastructure

June 27 2022

Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced plans to further […]

Ginkgo Bioworks and First Serv Announce Plans to Develop and Implement Innovative Global Biosecurity Capabilities in Qatar

May 19 2022

Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, and First Serv, a […]